



DIASORIN SIGNS AGREEMENTS WITH UNIFARMA AND ALLIANCE HEALTHCARE FOR THE DISTRIBUTION IN ITALIAN PHARMACIES OF THE LIAISON® IQ AND THE TWO POINT-OF-CARE TESTS FOR COVID-19

Saluggia, June 3, 2021 - DiaSorin (FTSE MIB: DIA) signed agreements with Unifarma and Alliance Healthcare for the distribution and sale in Italian pharmacies of the LIAISON® IQ, an immunodiagnostic Point-of-Care (POC) platform, and the first two tests based on lateral flow technology available for use on it, the LIAISON® Quick Detect COVID TrimericS Ab and the LIAISON® Quick Detect COVID Ag.

The LIAISON® Quick Detect COVID TrimericS Ab, in particular, detects specific IgG antibodies against SARS-CoV-2 Spike Protein in human capillary blood from a fingerstick in 10 minutes and it can establish if a patient has had an adaptive immune response to COVID-19 triggered either by a natural infection or by a vaccine. The LIAISON® Quick Detect COVID Ag, on the other hand, allows the detection of SARS-CoV-2 antigen through nasal and nasopharyngeal swabs, thus identifying people with an active COVID-19 infection.

DiaSorin signed an agreement with Alliance Healthcare Italia, the Walgreens Boots Alliance division dedicated to distribution and wholesale of pharmaceuticals in more than 9,000 pharmacies across Italy. According to it, Alliance Healthcare Italia will manage sales in all Italian regions and territories except for Piedmont and Valle D'Aosta regions, together with some specific areas of Lombardy and Liguria regions. According to the separate agreement signed by DiaSorin these specific areas will be served exclusively by Unifarma, leader in the distribution of pharmaceuticals and parapharmaceuticals in Northwestern Italy with a service dedicated only to the more than 2,600 pharmacies served daily.

In Italy, there are more than 19,500 pharmacies¹, with a per capita distribution in line with the European average. This data confirms how widespread pharmacies are and shows how they are an extremely suitable place for running diagnostic tests for diagnosing COVID-19, for monitoring the effectiveness of the vaccination programs and for screening the population.

Carlo Rosa, CEO of the DiaSorin Group, commented: *“The agreements signed with Unifarma and Alliance Healthcare will make even more accessible and simple for people to get tested for COVID-19. Our high-quality solutions will, in fact be run on our LIAISON IQ, an innovative platform that provides reliable results quickly and that is able to guarantee full traceability of the results through a barcode system.”*

¹ According to 2019 Federfarma data



For additional information, please contact:

Riccardo Fava

Corporate Vice President Communication & Investor Relations

Tel: +39.0161.487988

riccardo.fava@diasorin.it

Emanuela Salvini

Investor Relator

Tel: +39.0161.487567

emanuela.salvini@diasorin.it

About DiaSorin

Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field, with 26 companies, 4 branches, 5 manufacturing facilities and 5 research and development centers.

For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide.

The extensive diagnostic testing offer, made available through continuous investments in research, positions DiaSorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the “Diagnostic Specialist”.

More info at www.diasoringroup.com